Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
ALLERGY AND DERMATOLOGY: ATOPIC DERMATITIS

EFFICACY AND SAFETY OF TACROLIMUS OINTMENT COMPARED WITH THAT OF HYDROCORTISONE ACETATE OINTMENT IN CHILDREN WITH ATOPIC DERMATITIS

Stacie M. Jones
Pediatrics August 2003, 112 (Supplement 2) 461-462;
Stacie M. Jones
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • Comments
Loading
Download PDF

Reitamo S, Van Leent EJM, Ho V, et al. J Allergy Clin Immunol. 2002;109:539–546

Purpose of the Study.

To compare 0.03% and 0.1% tacrolimus ointment with 1% hydrocortisone acetate ointment in children 2 to 15 years of age with moderate-to-severe atopic dermatitis (AD).

Study Population.

Children ages 2 to 15 years with a diagnosis of AD were recruited from 27 centers in 6 European countries and Canada. Patients were required to have a severity grading of moderate to severe (using established criteria) and at least 5%, but not >60%, total body surface area (BSA) involvement.

Methods.

This was a phase III, multicenter, randomized, double-blind, parallel-group trial. Patients were randomized (1:1:1) to receive 0.03% or 0.1% tacrolimus or 1% hydrocortisone acetate. Treatment included application of a thin layer of ointment twice daily to active skin lesions until clearing of lesions for 7 days. Other therapies were prohibited with the exception of inhaled or intranasal corticosteroids (maximum dose: 1 mg/day) and nonmedicated emollients or bath oils. Assessments were at baseline, days 3 and 7 and weeks 2 and 3 of treatment and 2 weeks after completing treatment (week 5). Assessments included investigator rating of skin disease and BSA involvement and patient symptoms assessment symptoms. These were used to calculate the modified eczema area and severity index (mEASI). A graded physician’s global evaluation regarding clinical response was also included. Adverse events and laboratory assessments were obtained.

Results.

A total of 560 patients were enrolled. Study discontinuations were as follows: 21 of 189 in 0.03% tacrolimus group, 13 of 186 in 0.1% tacrolimus group, and 20 of 185 in hydrocortisone group. The mEASI, mean area under the curve (mAUC) as percentage of baseline showed the 0.03% tacrolimus (44.8%) and 0.1% tacrolimus (39.8%) to be more effective than 1% hydrocortisone (64%), and 0.1% tacrolimus to be the most effective treatment. Transient skin-burning was reported more often in the tacrolimus groups. Laboratory parameters showed no treatment differences and no significant changes between groups.

Conclusions.

Tacrolimus 0.03% and 0.1% ointments were more effective and showed equivalent safety when compared with 1% hydrocortisone in the treatment of children with moderate-to-severe AD.

Reviewer’s Comments.

This study demonstrates the usefulness and safety of tacrolimus ointment for children with moderate-to-severe AD. This new class of nonsteroid, immunomodulatory medications provides important therapeutic alternatives to long-term corticosteroid therapies for young children.

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 112, Issue Supplement 2
1 Aug 2003
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
EFFICACY AND SAFETY OF TACROLIMUS OINTMENT COMPARED WITH THAT OF HYDROCORTISONE ACETATE OINTMENT IN CHILDREN WITH ATOPIC DERMATITIS
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
EFFICACY AND SAFETY OF TACROLIMUS OINTMENT COMPARED WITH THAT OF HYDROCORTISONE ACETATE OINTMENT IN CHILDREN WITH ATOPIC DERMATITIS
Stacie M. Jones
Pediatrics Aug 2003, 112 (Supplement 2) 461-462;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
EFFICACY AND SAFETY OF TACROLIMUS OINTMENT COMPARED WITH THAT OF HYDROCORTISONE ACETATE OINTMENT IN CHILDREN WITH ATOPIC DERMATITIS
Stacie M. Jones
Pediatrics Aug 2003, 112 (Supplement 2) 461-462;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Purpose of the Study.
    • Study Population.
    • Methods.
    • Results.
    • Conclusions.
    • Reviewer’s Comments.
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

ALLERGY AND DERMATOLOGY: ATOPIC DERMATITIS

  • ENDOGENOUS ANTIMICROBIAL PEPTIDES AND SKIN INFECTIONS IN ATOPIC DERMATITIS
  • LONG-TERM TREATMENT WITH CETIRIZINE OF INFANTS WITH ATOPIC DERMATITIS: A MULTI-COUNTRY, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (THE ETAC TRIAL) OVER 18 MONTHS
Show more ALLERGY AND DERMATOLOGY: ATOPIC DERMATITIS

ABSTRACTS

  • ENDOGENOUS ANTIMICROBIAL PEPTIDES AND SKIN INFECTIONS IN ATOPIC DERMATITIS
  • LONG-TERM TREATMENT WITH CETIRIZINE OF INFANTS WITH ATOPIC DERMATITIS: A MULTI-COUNTRY, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL (THE ETAC TRIAL) OVER 18 MONTHS
  • PLEIOTROPIC EFFECT IN LYMPHOCYTE ACTIVATION CAUSED BY CASPASE-8 MUTATIONS LEAD TO HUMAN IMMUNODEFICIENCY
Show more ABSTRACTS

Similar Articles

  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics